Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease

Sofía Garcés(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(Chinese Academy of Agricultural Sciences)

Modern Pathology

June 30, 2017

10.1038/modpathol.2017.55

Cited by 292

Related Papers

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

|Blood|2007|298

Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

|Journal of Hematology & Oncology|2015|139

<i><scp>MYC</scp>/<scp>BCL</scp>6</i> double‐hit lymphoma (<scp>DHL</scp>): a tumour associated with an aggressive clinical course and poor prognosis

|Histopathology|2015|106

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients

|American Journal of Hematology|2020|84

Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia

|Haematologica|2018|82